Genmab released its Q2 17 results, wherein revenue and profitability came in slightly ahead of our estimates as well as market consensus. Reported revenue increased to DKK773.3m (vs AV’s estimate: DKK763m; Q1 17: DKK250.8m) primarily driven by higher than expected milestone income from the multiple myeloma/MM drug ‘Darzalex’ (DKK489m vs AV’s estimate: DKK475m; mainly related to second-line approval in Europe and third-line approval in the US). Net sales for the drug re
21 Sep 2017
Decent set of results; encouraging data in front-line multiple myeloma setting
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Decent set of results; encouraging data in front-line multiple myeloma setting
Genmab A/S (GMAB:WBO) | 0 0 1.3% | Mkt Cap: 66,508m
- Published:
21 Sep 2017 -
Author:
Sumit Sayal -
Pages:
3
Genmab released its Q2 17 results, wherein revenue and profitability came in slightly ahead of our estimates as well as market consensus. Reported revenue increased to DKK773.3m (vs AV’s estimate: DKK763m; Q1 17: DKK250.8m) primarily driven by higher than expected milestone income from the multiple myeloma/MM drug ‘Darzalex’ (DKK489m vs AV’s estimate: DKK475m; mainly related to second-line approval in Europe and third-line approval in the US). Net sales for the drug re